Latest Close
$1.44
Stock Hub
FBLG
FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
-$10.34 (-87.78%)
Market Cap
$9,587,798.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
none
52W Range
$0.62 to $12.80
Target Mean Price
$12.50
Beta
1.22
Trailing P/E
Not available
Forward P/E
-0.44
Price / Book
1.89
Company Overview
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.